Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
any thoughts on IFHR? Worth watching?
Someone who is trying to get filled at .0003 is getting partials in thousand of shares. Can't make them happy. MMs are funny when it comes to fooling around with a stock. Will be nice to get some renewed interest and news here.
Nice 1000 sh trade - sketchy. Not sure if it was a partial buy? Doesnt make sense that it is someone selling. Otherwise mm skimming from an open order to keep price down?
Back to waiting game - if there is going to be a merger, the first hint of news will send this skyhigh IMO
The massive volume is deafening.
Hopefully things start to pick up towards the end of the week. Maybe Bass will begin to answer a few of the many questions that exist
Anyone want to wager a bet....that AF has something to say this weekend?
Can we get a Russell3000 squeeeeze run out of those that are short?
BTW - those last comments are one of the major reasons why I have held the majority of my position in this stock. While FDA approval is not certain, I do believe that there are other current opportunities for use of ampligen that should bring value. Dickey's hiring provided further support for me.
Just to reiterate, not sure if this poster is actually there or if he is reporting 100% accurate info, although it does sound unbiased. His latest comments:
"Talking about the Sage Group and the tie in to Osaka. The Sage Group is working directly with Osaka and Tokyo to get Ampligen added as a vaccine adjuvant. It is required to get their season vaccine to work against the H1N1 variant.
Pandemic will most certainly cause the Japanese to order Ampligen to boost the season flu vaccine they have already stockpiled. "We think that there will be substantive orders through Biken for Ampligen as an adjuvant."
"Dickey is covering his background and why he is here.
He is here to work on partnering and licensing of Ampligen - both here and abroad.
Shareholders here were pleased with his comments."
Final point - take it for what it's worth:
"Personal observation - these are very serious people with a lot of gravitas involved in this. (Including some of the large shareholders sitting up front)
Dr. Mitchell is a Professor at Vanderbilt, Rob Dickey has been covered at length on this board. Chip Burnheart is very sharp as the CFO.
I'm feeling even more confident than ever after meeting them."
Further update - sounds like similar story to what we have been hearing, so nothing really new out of the company:
"Dr. Carter is giving his thoughts on the potential approval. Talks about 80% of NBE getting approved. He also states that the FDA hasn't asked for any clarifications or any additional information on the application. Both of those are very good signs.
He also is covering the compassionate use of Ampligen. Also a very positive sign for approval."
From Yahoo:
Proposal 1 - All 5 Directors have been elected.
Proposal 2 - Auditors have been ratified.
On proposal 3, the requirements are a majority of all shareholders of record to vote in favor. Since that is a higher requirement than just a majority of shareholders present at the meeting, that proposal will remain open for voting until July 28th.
Proposal 4 has been approved.
Meeting was formally adjourned. Now comes the round table discussion.
For those not following on Yahoo (message board sucks mostly), here is purported first hand account of meeting by starmandss :
The meeting is about to get underway. Dr. Carter and Rob Dickey both just walked around introducing themselves. There are a few employees here along with a few investors.
Agenda -
A. Meeting call to order
1. Introductions
2. Rules of Conduct
3. Existance of Quorum
4. Proof of mailing of Notice
B. proposals and Discussions
1. Proposal 1 - Election of the Board
- William A. Carter
- Richard C. Piani
- William M. Mitchell
- Iraj-Eqhbal Kiani
- Thomas K. Equels
2. Proposal 2 - ratification of Auditors
3. Proposal 3 - ammendment to the Certificate of Incorporation to increase the number of authorized shares to 350,000,000
4. Proposal 4 - Adoption of our 2009 Equity Incentive Plan
C. Voting
D. Questions for auditors
E. Results of voting
F. Adjournment
G. Chairman's Remarks
Dr. Carter just did introductions. Up front with him are Rick Finer SEC Counsel, Chip Burnheart CFO, Rob Dickey, Dr. Mitchell - Director.
In the audience are Dr. Russell Landers (?) and and Wayne Springer (?) both VPs with HEB.
They just validated the quorum.
Holding up pretty well this morning - will go big one way or another following meeting.
If down, most likely due to irrational investor sentiment and stop losses being triggered.
If up, short squeeze
Should be an interesting next few hours
If the meeting gets canceled, that is on the shareholders not on the company. Their stated reasons were, if we do not have a quorum, then we will have to cancel the meeting. What that means is they will not have enough voting shares present to make any decisions.
If shareholders are as interested in answers as you are - then they should show up or proxy their votes.
Be interesting to see short interest after trading yesterday and this morning. If positive news released at Annual Meeting and short interest is as high as I think it is, we could have a very good run back to previous levels.
everything is contingent upon either FDA approval or progressing the flu vaccine promise. So, if no news on either front, pretty easy to believe the stories.
Only time will tell which side is telling the truth and which side has been pumping the market with stories. Interesting action a day before the annual meeting - hopefully positive update will come out of tomorrow.
Market generally in a red sell-off mood. That combined with AF article is resulting in drop on relatively low volume. Should be interesting to see if there is the usual .10+ cent spike near EOD.
.0005 x .0006 - once those 6's start hitting, going to get very interesting
But doesn't this sound like a guy whose expertise would be in looking into strategic merger/acquisition options?
http://www.sagehealthcare.com/the-sage-team.aspx
Mr. Dickey combines experience in entrepreneurial management with a background in capital markets, transaction structuring and merger and acquisitions (M&A). He is a Managing Director of DSS Partners LLC, an entity engaged in acquiring or in-licensing promising drug candidates and providing hands-on financial and technical management for their development.
Mr. Dickey joined an oncology-focused drug development company, Protarga, in 1996 as its fourth employee, first as CFO, and then in 2003 as its President, CEO and CFO. During this period, the company advanced from discovery stage to 60 employees and a new cancer drug in pivotal Phase III clinical studies. He raised $57 million privately for Protarga and oversaw its subsequent sale to Sankyo, the second largest pharmaceutical company in Japan.
Before joining Protarga, Mr. Dickey spent seventeen years as an investment banker, where he was involved in public and private offerings of debt and equity and in mergers and acquisitions for entrepreneurially-based companies as well as Fortune 100 corporations. For the four years prior to joining Protarga, Mr. Dickey was a Managing Director in the corporate finance department at Legg Mason Wood Walker. Before that he spent thirteen years at Lehman Brothers in New York, lastly as a Senior Vice President in its M&A Department and then as a founder and partner in its middle market investment banking group affiliate.
Mr. Dickey received a B.A. from Princeton University and an M.B.A. from The Wharton School, University of Pennsylvania.
I like slow and steady rise - followed by volume explosion
Couple real interesting points:
1. Mr. Dickey will receive four year options to purchase up to 150,000 shares of our common stock at an exercise price of $2.81 per shares. [This is well above current price]
2. His options will vest in full after 3 months if there is a change in control.
One has to wonder if they are looking at approval and then ways to get bought out b/c it probably does not make economic sense for them to expand in order to capture full CFS/swine fly market.
That is why the fluctuations - day traders having a field day with this. Any sudden movement down triggers an avalanche of sells because people think that FDA has denied. Any sudden movement up triggers an avalanche of buys because people think that there has been an approval.
Until news comes out - the low/high does nothing other than frustrate those who own it. And makes the day traders happy if they can catch the waves.
One good question is whether a substantial portion of the possibility of a complete response letter is already factored into the stock price - and how far is the bottom if one is received.
yeah, so the question is, how big a mess is this for nite and how much can the collective group profit!
Don't think it would be the caveat emptor because I was able to buy a few days ago with no problems
Interesting, scotty put a trade restriction on it. Was selling it before.
Here comes the run...do do do doo
Have to have balls of steel at this point with this stock b/c any sudden movements left or right and you see a run, which, without news, really doesnt mean much.
3 mill share trade at .0004 - run starting?
Further disclaimer - my last post was not a buy/sell recomendation. Just thought it may be useful to those who are not aware of the rules, as relayed to me by their IR person.
It is quite possible they have not yet heard anything and are still waiting to release info.
Just FYI - I sold half my position, the silence seems to me that company may have heard something and if they have up to 4 days to report, that would allow them to sit on it until possibly tomorrow (if they heard on Monday). If/when they release info, and if it is negative, I will probably load back up as it will be oversold on the news and investor panic and I still think the flu adjuvant potential is viable.
Sent: Wednesday, June 10, 2009 12:49 PM
To: ir@hemispherx.net
Subject: FDA correspondence
2 Questions:
1. How long is the company allowed to wait before announcing receipt of either an approval letter or a complete response letter? [The SEC allows companies up to 4 business days to report material events.]
2. If no decision has been reached by the FDA, has the company been in contact with them about anticipated response date? [The company has no additional information to report.]
If it was possible that the knew and were not telling us (and this didn't violate any securities laws), I would imagine that Adam F would have raised that point by now.
Called the IR lady, and her answering machine says working out of the office and checking messages. I wonder if she is in Philly?
speculative biopharma stock - have to take the bad with the potential for great
Nothing like being held hostage
boxed in again 2.96 x 2.96, did similar thing yesterday before spiking over 3.20 and retracing back.
Should be interesting to see how many people hold this until an announcement is made. Suspense is eating into people as evidenced by ease in which mm has been manipulating stock price
The pre-FDA decision trading range seems to be between 2.95 and 3.05.
well, that was fun. Wish I had held some and was able to buy in at that level
MMs feeding off uncertainty and stop losses - easy shake down.
So...do we get news after market close or before market opens
Right, but the decision date in the PR was for the 25th